



**TB CARE I**

**TB CARE I - Nigeria**

**Year 4 Extension  
Monitoring Report  
April 2015 - June 2015**

**Submission date: July 30, 2015**

TB CARE I project extension June 2015 (Summary)			Implementation periods						Remarks and Justification	Activity Status (Q2)		
Code of activity	Description Activity	Partners	Jan	Feb	March	April	May	June		April -June 2015	Progress to date (% of all implementation period activities complete)	Remarks (Reason for not completing activity as scheduled/Other key information)
1	1. Development assessment tool/template	KNCV							Request by USAID Mission, to ensure effective and efficient investment of USAID support	85% of the activity has been completed	The finalization and submission of the report is expected in July or beginning of August 2015	
2	2. Baseline data analysis per state and prioritizing interventions	KNCV										
3	3. Compilation of State Baseline data (report)	KNCV										
4	4. Provision of continuation of care for 120 MDR TB patients and support enrollment for additional 60 patients; support and supervision	KNCV							Currently supporting ambulatory PMDT in 8 states (Lagos, Ogun, Abia, Akwa Ibom, Benue, Kaduna, Kano and Gombe), new patients can equally be enrolled.	100% of activities completed	The activity started in 8 states. In 2014 (Quarter 3) the states Oyo and Osun were added. In total, the TB CARE I project is supporting ambulatory PMDT in 10 states.	
5	5. Procurement of 6,000 and distribution of Rif/MDR TB Cartridges for 6 months	KNCV							<p>TB CARE I during this quarter continued to provide support for cartridge distribution to a total of 31 Gene Xpert sites. Of the total stock of 6,000 only 400 cartridges were distributed to two sites, while the remaining 5,600 were destroyed by a fire accident that occurred at the SCMS warehouse in Abuja where the cartridges were stored. Prior to the fire incident TB CARE I had 3,400 cartridges in stock which were distributed and through concerted efforts, TB CARE I took delivery of additional 3,200 cartridges from NTP Central Store and distributed to the sites. In all, 7,000 cartridges were distributed to the Gene Xpert sites. A total of 4,598 sputa were tested of which 4,154 (90.3%) were successful tests. Further analysis of the data show that a total of 1,004 (24.2%) MTB cases were detected of which 150 (3.6%) were Rif+ cases.</p>	100% of activities completed		
6	6. Supervision to 15 high challenged sites of the 31	KNCV							To ensure effective utilization and maintenance of machines before new mechanism or GF/GoN takes over	100% of activity completed		
7	7. Hosting E-TB Manager for 2 quarters	MSH KNCV							The only M&E system for DR TB at the moment and the need to customize to entire TB program	100% of activity completed		
8	8. Staffing & Operations	MSH KNCV										
<b>Planned Deliverables</b>									<b>Actuals</b>			
1	10 States base line data								12 States TB baseline assessment conducted and necessary information obtained			
2	160 MDR TB patients supported for ambulatory PMDT								203 MDR TB patients supported for ambulatory PMDT (125 from last year and 78 enrolled in current plan)			
3	6,000 sputa tested by Xpert from DR-TB suspects and PLHIV								4,598 sputa tested by Xpert from DR-TB suspects and PLHIV. Cumulatively a total of 9,218 were tested in the current plan			
4	e-TB manager customized for M&E for the entire TB program including DR-TB handed over to NTP/GF								e-tb manager customized for DR TB and handed over to NTP. Administrative test of customized e-tb Manager for DS TB is currently ongoing. Handover will be arranged after training.			